Funding round-up: Atara, TherapeuticsMD, ReNeuron
Atara Biotherapeutics Inc. (NASDAQ:ATRA) and TherapeuticsMD Inc. (NYSE-M:TXMD) raised a combined $210 million in follow-on offerings, while ReNeuron Group plc (LSE:RENE) raised L68.4 million ($106.5 million) in a conditional placing.
Atara raised $180 million through the sale of 3.5 million shares at $52 in a follow-on underwritten by Goldman Sachs; Citigroup; William Blair; Canaccord; and JMP Securities. Atara proposed the offering after market close on Tuesday, when its shares were valued at $46.32. The company gained $0.76 to $54.17 on Friday. Last month, Atara exercised an exclusive, worldwide option to develop and commercialize three allogeneic T cell therapy programs from Memorial Sloan Kettering Cancer Center (see BioCentury Extra, June 15). ...